Primerica Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong ISP-driven growth with adjusted operating revenues up 9% and EPS up 19% year-over-year. Term Life remained stable, while local event strategies and new incentives aim to boost recruiting. Full-year guidance anticipates continued ISP growth and stable margins.
Fiscal Year 2025
-
Record 2025 results featured 10% net operating income growth, 16% EPS growth, and robust capital returns. ISP sales surged 24% year-over-year, while term life faced headwinds but is expected to recover as economic pressures ease. 2026 guidance calls for stable margins and continued investment.
-
Q3 2025 saw strong earnings and cash flow growth, with adjusted net operating income up 7% and robust ISP segment performance. Life sales declined due to economic pressures, but investment and mortgage businesses posted double-digit growth. Capital return and cash generation remain industry-leading.
-
Q2 2025 saw strong earnings growth, with adjusted net operating income up 6% and robust ISP segment performance offsetting term life headwinds. Recruiting remained strong, capital returns to stockholders were significant, and guidance for ISP sales growth was raised above 10%.
-
Q1 2025 saw strong earnings growth, with adjusted net operating income up 14% and robust ISP and mortgage sales, despite economic uncertainty impacting recruiting and Term Life sales. Full-year guidance remains steady, with continued capital returns and stable risk metrics.
Fiscal Year 2024
-
Record 2024 results included double-digit growth in adjusted income, robust ISP sales, and a 79% capital return to shareholders. Outlook for 2025 is conservative due to cost-of-living headwinds and market uncertainty, with continued investment in technology and distribution.
-
Double-digit growth in adjusted operating earnings and EPS was driven by strong recruiting, robust investment and savings product sales, and favorable market conditions. The exit from the senior health business generated a significant tax benefit, and capital returns to shareholders remained high.
-
Double-digit adjusted earnings growth and strong recruiting drove solid Q2 results, with robust investment product sales and stable key financial ratios. The exit from Senior Health and continued capital returns marked significant developments.